Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID

Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cardinali, Daniel P.
Formato: Artículo revista
Lenguaje:Español
Publicado: Asociación de Medicina del Estrés y Psicoinmunoneuroendocrinología 2023
Materias:
COVID-19
deterioro cognitivo mínimo
encefalomielitis miálgica/síndrome de fatiga crónica
melatonina
minimal cognitive impairment
myalgic encephalomyelitis/chronic fatigue syndrome
melatonin
comprometimento cognitivo mínimo
encefalomielite miálgica/síndrome de fadiga crônica
Acceso en línea:https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717
Aporte de:
Pinelatinoamericana de Universidad Nacional de Córdoba
id I10-R287-article-39717
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-287
container_title_str Pinelatinoamericana
language Español
format Artículo revista
topic COVID-19
deterioro cognitivo mínimo
encefalomielitis miálgica/síndrome de fatiga crónica
melatonina
COVID-19
minimal cognitive impairment
myalgic encephalomyelitis/chronic fatigue syndrome
melatonin
COVID-19
comprometimento cognitivo mínimo
encefalomielite miálgica/síndrome de fadiga crônica
melatonina
spellingShingle COVID-19
deterioro cognitivo mínimo
encefalomielitis miálgica/síndrome de fatiga crónica
melatonina
COVID-19
minimal cognitive impairment
myalgic encephalomyelitis/chronic fatigue syndrome
melatonin
COVID-19
comprometimento cognitivo mínimo
encefalomielite miálgica/síndrome de fadiga crônica
melatonina
Cardinali, Daniel P.
Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
topic_facet COVID-19
deterioro cognitivo mínimo
encefalomielitis miálgica/síndrome de fatiga crónica
melatonina
COVID-19
minimal cognitive impairment
myalgic encephalomyelitis/chronic fatigue syndrome
melatonin
COVID-19
comprometimento cognitivo mínimo
encefalomielite miálgica/síndrome de fadiga crônica
melatonina
author Cardinali, Daniel P.
author_facet Cardinali, Daniel P.
author_sort Cardinali, Daniel P.
title Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
title_short Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
title_full Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
title_fullStr Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
title_full_unstemmed Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
title_sort melatonin: a frustrated hope in the acute phase of the covid-19 pandemic, a therapeutic possibility in prolonged covid
description Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID patients in the intensive care unit. Furthermore, as a cytoprotectant, melatonin helps to prevent a number of comorbidities of COVID-19, such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. The clinical sequelae and symptoms of many patients with COVID-19 can persist for months beyond the acute stage of SARS-CoV-2 infection, the so-called “long COVID”. Melatonin, as a neuroprotective agent, emerges as an excellent agent to control cognitive impairment ("brain fog") and pain in myalgic encephalomyelitis/chronic fatigue syndrome, like that documented in prolonged COVID.
publisher Asociación de Medicina del Estrés y Psicoinmunoneuroendocrinología
publishDate 2023
url https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717
work_keys_str_mv AT cardinalidanielp melatoninafrustratedhopeintheacutephaseofthecovid19pandemicatherapeuticpossibilityinprolongedcovid
AT cardinalidanielp lamelatoninaunaesperanzafrustradaenlafaseagudadelapandemiacovid19unaposibilidadterapeuticaenelcovidprolongado
AT cardinalidanielp melatoninaumaesperancafrustradanafaseagudadapandemiadecovid19umapossibilidadeterapeuticanacovidprolongada
first_indexed 2024-09-03T22:41:57Z
last_indexed 2024-09-03T22:41:57Z
_version_ 1809216508962799616
spelling I10-R287-article-397172024-05-22T19:24:41Z Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID La melatonina: Una esperanza frustrada en la fase aguda de la pandemia COVID-19, una posibilidad terapéutica en el COVID prolongado Melatonina : Uma esperança frustrada na fase aguda da pandemia de COVID-19, uma possibilidade terapêutica na COVID prolongada Cardinali, Daniel P. COVID-19 deterioro cognitivo mínimo encefalomielitis miálgica/síndrome de fatiga crónica melatonina COVID-19 minimal cognitive impairment myalgic encephalomyelitis/chronic fatigue syndrome melatonin COVID-19 comprometimento cognitivo mínimo encefalomielite miálgica/síndrome de fadiga crônica melatonina Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID patients in the intensive care unit. Furthermore, as a cytoprotectant, melatonin helps to prevent a number of comorbidities of COVID-19, such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. The clinical sequelae and symptoms of many patients with COVID-19 can persist for months beyond the acute stage of SARS-CoV-2 infection, the so-called “long COVID”. Melatonin, as a neuroprotective agent, emerges as an excellent agent to control cognitive impairment ("brain fog") and pain in myalgic encephalomyelitis/chronic fatigue syndrome, like that documented in prolonged COVID. La melatonina es particularmente eficaz para reducir los signos y síntomas de la infección por SARS-CoV-2 debido a sus funciones como agente antioxidante, antiinflamatorio e inmunomodulador. La melatonina es también un medicamento cronobiótico / hipnótico eficaz para tratar el delirio y restaurar el desequilibrio circadiano en pacientes con COVID en la unidad de cuidados intensivos. Además, como citoprotector, la melatonina ayuda a prevenir una serie de comorbilidades del COVID-19, como la diabetes, el síndrome metabólico y las enfermedades cardiovasculares isquémicas y no isquémicas. Las secuelas clínicas y los síntomas de un número considerable de pacientes con COVID-19 pueden persistir durante meses más allá de la etapa aguda de la infección por SARS-CoV-2, el llamado “COVID largo”. La melatonina, como agente neuroprotector, emerge como un excelente agente para controlar el deterioro cognitivo ("niebla cerebral") y el dolor en la encefalomielitis miálgica/síndrome de fatiga crónica, similar a la documentada en el COVID prolongado. A melatonina é particularmente eficaz na redução dos sinais e sintomas da infecção por SARS-CoV-2 devido ao seu papel como agente antioxidante, anti-inflamatório e imunomodulador. A melatonina também é um medicamento cronobiótico/hipnótico eficaz para tratar delirium e restaurar o desequilíbrio circadiano em pacientes com COVID na unidade de terapia intensiva. Além disso, como citoprotetor, a melatonina ajuda a prevenir várias comorbidades do COVID-19, como diabetes, síndrome metabólica e doenças cardiovasculares isquêmicas e não isquêmicas. As sequelas clínicas e os sintomas de um número considerável de pacientes com COVID-19 podem persistir por meses além do estágio agudo da infecção por SARS-CoV-2, o chamado “longo COVID”. A melatonina, como agente neuroprotetor, surge como um excelente agente para controlar o comprometimento cognitivo (“brain fog”) e a dor na encefalomielite miálgica/síndrome da fadiga crônica, semelhante ao documentado no COVID prolongado. Asociación de Medicina del Estrés y Psicoinmunoneuroendocrinología 2023-03-27 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html application/pdf https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717 ark:/s27968677/rkk8rlykb Pinelatinoamericana; Vol. 3 No. 1 (2023); 5-13 Pinelatinoamericana; Vol. 3 Núm. 1 (2023); 5-13 Pinelatinoamericana; V. 3 N. 1 (2023); 5-13 Pinelatinoamericana; v. 3 n. 1 (2023); 5-13 2796-8677 spa https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717/39868 https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717/40905 Derechos de autor 2023 Pinelatinoamericana https://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares